Clinical trial
Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects
NCT00328978 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00328978 |
|---|---|
| Title | Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects |
| Official title | A Canadian, Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment With Higher Doses of Quetiapine Fumarate (Seroquel®) Greater Than 800 mg/Day in Schizophrenic or Schizoaffective Subjects. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorders |
| Intervention type | Drug |
| Interventions | Quetiapine |
| Enrollment | 330 |
| Start date | Oct 1, 2003 |
| Completion | Sep 1, 2005 |
| First posted | May 24, 2006 |
| Last update posted | Mar 25, 2009 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: